Cargando…

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

PURPOSE: Dinutuximab (Unituxin™; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma. United Therapeutics Corporation (UTC) assumed ch14.18 production from the National Cancer Institute (NCI); this study eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marachelian, Araz, Desai, Ami, Balis, Frank, Katzenstein, Howard, Qayed, Muna, Armstrong, Michael, Neville, Kathleen A., Cohn, Susan L., Bush, Mark, Gunawan, Rudy, Lim, Allison Pecha, Smith, Malcolm A., Mary Smith, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747995/ https://www.ncbi.nlm.nih.gov/pubmed/26791869 http://dx.doi.org/10.1007/s00280-015-2955-9

Ejemplares similares

IMMU-02. CH14.18 IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: A META-ANALYSIS
por: Abdel-Khaleq, Sameerah, et al.
Publicado: (2021)

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
por: Ozkaynak, M. Fevzi, et al.
Publicado: (2018)

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
por: Ozkaynak, M. Fevzi, et al.
Publicado: (2018)

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
por: Simon, Thorsten, et al.
Publicado: (2011)

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD(2) Antibody
por: Siebert, Nikolai, et al.
Publicado: (2014)

Myeloablative treatment supported by autologous stem cell infusion with neuroblastoma.
por: Ryu, Kyung Ha, et al.
Publicado: (2003)

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO
por: Mueller, Ina, et al.
Publicado: (2017)

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO
por: Siebert, Nikolai, et al.
Publicado: (2020)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
por: Seitz, Christian Martin, et al.
Publicado: (2021)

Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2020)

The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
por: Zhu, Shengyun, et al.
Publicado: (2021)

Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells
por: Fisher, Jonathan P H, et al.
Publicado: (2015)

The Premalignant Ancestor Cell of t(14;18)(+) Lymphoma
por: Brisou, Gabriel, et al.
Publicado: (2021)

Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia
por: Terme, Mickaël, et al.
Publicado: (2014)

Correction: The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
Publicado: (2022)

The Evolution of Risk Classification for Neuroblastoma
por: Sokol, Elizabeth, et al.
Publicado: (2019)

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
por: Bodo, Juraj, et al.
Publicado: (2016)

Correction: Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia
Publicado: (2014)

1418. Injections and Infections: Understanding Harm Reduction Utilization in a Rural State
por: Thakarar, Kinna, et al.
Publicado: (2020)

1418. Clinical Characteristics of Vertebral Osteomyelitis in Cancer Patients
por: Fukushima, Kazuaki, et al.
Publicado: (2019)

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
por: Troschke-Meurer, Sascha, et al.
Publicado: (2019)

17230 Agreement between point-of-care intestinal ultrasound (POCUS) and magnetic resonance enterography for assessment of the terminal ileum through sigmoid colon in pediatric patients with inflammatory bowel diseases: A diagnostic cross-sectional study
por: Chavannes, Mallory, et al.
Publicado: (2021)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas
por: Salaverria, Itziar, et al.
Publicado: (2023)

Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma
por: Lascano, Danny, et al.
Publicado: (2023)

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
por: Goldberg, Jacob L, et al.
Publicado: (2020)

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study
por: Kang, Min H, et al.
Publicado: (2014)

Complete genome sequence of Hirschia baltica type strain (IFAM 1418(T))
por: Chertkov, Olga, et al.
Publicado: (2011)

Synthesis and Biological Characterization of the New Glycolipid Lactose Undecylenate (URB1418)
por: Verboni, Michele, et al.
Publicado: (2022)

Upfront consolidation treatment with (131)I‐mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high‐risk neuroblastoma
por: Feng, Jianhua, et al.
Publicado: (2020)

Correction: Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
Publicado: (2020)

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
por: Siebert, Nikolai, et al.
Publicado: (2018)

Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography for Follow-Up of 13-cis-Retinoic Acid Treatment for Residual Neuroblastoma After Myeloablative Chemotherapy
por: Sato, Yuya, et al.
Publicado: (2015)

Comparison of Non-myeloablative Conditioning Regimens for Lymphoproliferative Disorders
por: Hong, Sanghee, et al.
Publicado: (2014)

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
por: Berko, Esther R., et al.
Publicado: (2023)

Relapse of follicular lymphoma arising from a non‐t(14;18) clone
por: Otsuka, Yasuyuki, et al.
Publicado: (2020)

Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma
por: Panjan, Matej, et al.
Publicado: (2023)

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma
por: Bao, Riyue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_moca5fd1h6dvm47d0rac2htm4d